Although anti-IL-33 treatment has been shown to attenuate deleterious type 2 memory responses during rhinovirus infection, thereby reducing airway hyperresponsiveness [128], the specific mechanisms by which IL-33 regulates CD4+ T cells in SARS-CoV-2 infection remain to be explored. This evidence concerns the gene IL33 and airway hyperresponsiveness.